Astria Therapeutics chooses Ypsomed’s autoinjector for hereditary angioedema drug

Astria Therapeutics has partnered with Ypsomed to utilize its Ypsomate autoinjector for the administration of STAR-0215, aimed at treating hereditary angioedema (HAE). Astria, a US-based company, has developed STAR-0215, a long-acting monoclonal antibody inhibitor targeting plasma kallikrein, specifically designed to combat HAE. This drug secured fast track designation from the US Food and Drug Administration (FDA) last year and is currently being assessed in the Phase Ib/II ALPHA-STAR trial (NCT05695248).

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling, often due to either low levels or malfunctioning of the C1 inhibitor protein. Initial results from the ALPHA-STAR trial, released in March 2024, demonstrated that STAR-0215, administered once or twice within six months, was able to reduce monthly HAE attack rates by approximately 90%-96%.

Ypsomed, a Swiss medtech company, offers the Ypsomate autoinjector in various sizes, suitable for self-administration of liquid medications. Astria plans to launch STAR-0215 with the Ypsomed YpsoMate autoinjector and a pre-filled syringe, pending regulatory approval. The goal is to create an HAE therapy that provides flexibility for patients, allowing them to choose an administration method that best fits their lifestyle, with options for infrequent dosing every three to six months.

John Ruesch, Senior Vice President of Pharmaceutical Sciences and Technical Operations at Astria, emphasized the significance of the partnership with Ypsomed. He stated, “Our partnership with Ypsomed, a leading developer and manufacturer of injection systems, supports this goal through the planned development of an autoinjector that enables our vision for STAR-0215 to be a therapy that can effectively protect against HAE attacks while also having a very low burden of treatment and administration.”

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!